Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial

Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial is a phase 3, randomised interventional study registered as NCT06593431 by M.D. Anderson Cancer Center, with a registry enrolment figure of 80 participants, started 2024-10-23 and due to reach its primary completion in 2029-06-29. Interventions recorded: Consolidative Radiation. Conditions listed: Pancreas Cancer; Oligometastatic. Primary outcome: Safety and Adverse Events (AEs). Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed pancreatic ductal adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.